ergoloid mesylate Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Ergoloid mesylates (USAN), co-dergocrine mesilate (BAN) or dihydroergotoxine mesylate, trade name Hydergine, is a mixture of the methanesulfonate salts of three dihydrogenated ergot alkaloids.   Wikipedia

Chemistry

  • SMILES: CCC(C)[C@@H]1N2C(=O)[C@](NC(=O)[C@@H]3C[C@H]4[C@@H](Cc5c[nH]c6cccc4c56)N(C)C3)(O[C@@]2(O)[C@@H]7CCCN7C1=O)C(C)C.CC(C)C[C@@H]8N9C(=O)[C@](NC(=O)[C@@H]%10C[C@H]%11[C@@H](Cc%12c[nH]c%13cccc%11c%12%13)N(C)C%10)(O[C@@]9(O)[C@@H]%14CCCN%14C8=O)C(C)C.CC(C)[C@@H]%15N%16C(=O)[C@](NC(=O)[C@@H]%17C[C@H]%18[C@@H](Cc%19c[nH]c%20cccc%18c%19%20)N(C)C%17)(O[C@@]%16(O)[C@@H]%21CCCN%21C%15=O)C(C)C.CC(C)[C@@]%22(NC(=O)[C@@H]%23C[C@H]%24[C@@H](Cc%25c[nH]c%26cccc%24c%25%26)N(C)C%23)O[C@@]%27(O)[C@@H]%28CCCN%28C(=O)[C@H](Cc%29ccccc%29)N%27C%22=O
  • InChIKey: ZQLJWTRXKINMIN-BEJKIDSHSA-N
  • Mol. Mass: 2330.89
  • ALogP: Missing data
  • ChEMBL Molecules:
    ergoloid  
    ergoloid mesylates  
More Chemistry

Pharmacology

Alternative names

alkergot | circanol | codergine mesylate | codergocrine | co-dergocrine mesilate | codergocrine mesilate | co-dergocrine mesylate | codergocrine mesylate | co-dergocrine methanesulfonate | codergocrine methanesulfonate | deapril | deapril-st | dihydroergotoxine mesilate | dihydroergotoxine mesylate | dihydroergotoxine methanesulfonate | dihydroergotoxine methanesulfonates | dihydroergotoxine monomethanesulfonate | dihydrogenated ergot alkaloids | ergoloid mesilates | ergoloid mesylate | ergoloid mesylates | ergoloid methanesulfonate | ergoloid methanesulfonates | gerimal | hydergine | hydergine lc | hydrogenated ergot alkaloids

Organizations (23)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (20)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (1)


 

Migraine Disorders

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Dementia, Vascular (Phase 2)

Fragile X Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue